arrow
S

Stephen Devereux

idibaps
H指数:47
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features
2022-11-0428
OAAI
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study

依鲁替尼一线治疗CLL/SLL患者的长期疗效和安全性: 3期RESONATE-2研究的5年随访

LEUKEMIA
IF13.4
2019-10-18367
OAAI
Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis
2019-03-0831
OAAI
Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naive patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies
2018-10-0922
OAAI
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2
2018-06-07118
OAAI
Unmutated IGHV is not an adverse predictor of outcome to therapy with ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
2017-07-012
PRE
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
2015-12-171.3K
OAAI
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
2014-07-171.4K
OAAI